LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Stefano Brignola"
  2. AU="Nierzwicki, Łukasz"
  3. AU="Benvin, Iva"
  4. AU="Sardesai, S. C."
  5. AU="Aldrees, Rana"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

    Giuseppe Nicolò Fanelli / Carlo Alberto Dal Pozzo / Ilaria Depetris / Marta Schirripa / Stefano Brignola / Paola Biason / Mariangela Balistreri / Luca Dal Santo / Sara Lonardi / Giada Munari / Fotios Loupakis / Matteo Fassan

    Cancer Cell International, Vol 20, Iss 1, Pp 1-

    2020  Band 12

    Abstract: Abstract Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs harbor a mutation in BRAF gene, a proto-oncogene involved in cell ... ...

    Abstract Abstract Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs harbor a mutation in BRAF gene, a proto-oncogene involved in cell proliferation, differentiation and survival through the MAPK signaling cascade. The acquisition of BRAF mutation is an early event in the “serrated” CRC carcinogenetic pathway and is associated with specific and aggressive clinico-pathological and molecular features. Despite that the presence of BRAF mutation is a well-recognized negative prognostic biomarker in metastatic CRC (mCRC), a great heterogeneity in survival outcome characterizes these patients, due to the complex, and still not completely fully elucidated, interactions between the clinical, genetic and epigenetic landscape of BRAF mutations. Because of the great aggressiveness of BRAF-mutated mCRCs, only 60% of patients can receive a second-line chemotherapy; so intensive combined and tailored first-line approach could be a potentially effective strategy, but to minimize the selective pressure of resistant clones and to reduce side effects, a better stratification of patients bearing BRAF mutations is needed.
    Schlagwörter BRAF mutation ; Colorectal cancer ; Personalized medicine ; Sequencing ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; Cytology ; QH573-671
    Thema/Rubrik (Code) 616 ; 610
    Sprache Englisch
    Erscheinungsdatum 2020-01-01T00:00:00Z
    Verlag BMC
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas

    Antonio Pellino / Stefano Brignola / Erika Riello / Monia Niero / Sabina Murgioni / Maria Guido / Floriana Nappo / Gianluca Businello / Marta Sbaraglia / Francesca Bergamo / Gaya Spolverato / Salvatore Pucciarelli / Stefano Merigliano / Pierluigi Pilati / Francesco Cavallin / Stefano Realdon / Fabio Farinati / Angelo Paolo Dei Tos / Vittorina Zagonel /
    Sara Lonardi / Fotios Loupakis / Matteo Fassan

    Journal of Personalized Medicine, Vol 11, Iss 1095, p

    2021  Band 1095

    Abstract: The tight junction protein claudin-18 (CLDN18), is often expressed in various cancer types including gastric (GC) and gastroesophageal adenocarcinomas (GECs). In the last years, the isoform CLDN18.2 emerged as a potential drug target in metastatic GCs, ... ...

    Abstract The tight junction protein claudin-18 (CLDN18), is often expressed in various cancer types including gastric (GC) and gastroesophageal adenocarcinomas (GECs). In the last years, the isoform CLDN18.2 emerged as a potential drug target in metastatic GCs, leading to the development of monoclonal antibodies against this protein. CLDN18.2 is the dominant isoform of CLDN18 in normal gastric and gastric cancer tissues. In this work, we evaluated the immunohistochemical (IHC) profile of CLDN18 and its correlation with clinical and histopathological features including p53, E-cadherin, MSH2, MSH6, MLH1, PMS2, HER2, EBER and PD-L1 combined positive score, in a large real-world and mono-institutional series of advanced GCs ( n = 280) and GECs ( n = 70). The association of IHC results with survival outcomes was also investigated. High membranous CLDN18 expression (2+ and 3+ intensity ≥75%) was found in 117/350 (33.4%) samples analyzed. CLDN18 expression correlated with age <70 ( p = 0.0035), positive EBV status ( p = 0.002), high stage (III, IV) at diagnosis ( p = 0.003), peritoneal involvement ( p < 0.001) and lower incidence of liver metastases ( p = 0.013). CLDN18 did not correlate with overall survival. The predictive value of response of CLDN18 to targeted agents is under investigation in several clinical trials and further studies will be needed to select patients who could benefit from these therapies.
    Schlagwörter CLDN18.2 ; gastric adenocarcinoma ; biomarkers ; immunohistochemistry ; Medicine ; R
    Thema/Rubrik (Code) 616
    Sprache Englisch
    Erscheinungsdatum 2021-10-01T00:00:00Z
    Verlag MDPI AG
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang